Gilead’s twice-yearly antiviral protects against HIV infection in second large trial
Gilead said Thursday that its twice-yearly antiviral reduced the risk of HIV infections by 96% compared to an expected rate of infection in a second pivotal trial, paving the way for the likely approval of the drug for pre-exposure prophylaxis, or PrEP.
MIT researchers have developed a new HIV vaccination method that generates a strong immune response with just two doses, one ...
The Montgomery Advertiser on MSN1d
HIV stigma is on the decline for the first time in five years, new study findsHIV stigma, for the first time in five years, is on the decline in the United States, despite knowledge gaps in certain ...
Louisville Public Media on MSN4d
This preventive drug could be a 'game changer' in ending the HIV epidemicIn newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...
An event in Palm Springs will feature experts discussing updates in HIV research, as well as those living with HIV sharing ...
Black gay and bisexual men made up about 38% of the estimated 37,981 new HIV diagnoses in the U.S. in 2022. The Centers for Disease Control and Prevention estimates that approximately 50% of these men ...
ThePrint on MSN3d
Why Indian patients groups are opposing patent requests for blockbuster HIV drug lenacapavirGranting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...
One major reason why it has been difficult to develop an effective HIV vaccine is that the virus mutates very rapidly, ...
Progress in preventing infections was being made in the country with Europe's second-highest number of HIV cases. Then came ...
Gulu City leaders have linked new HIV infections among young people to cross-generational sex resulting from poolside parties ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback